标准与改良伊匹木单抗联合纳武利尤单抗治疗晚期肾细胞癌:随机II期试验(PRISM)
PRISM研究将192例初治晚期透明细胞肾细胞癌患者按2:1随机分配接受改良(每12周一次)或标准(每3周一次)伊匹木单抗联合纳武利尤单抗治疗。改良组3-5级治疗相关不良事件发生率显著低于标准组(32.8% vs 53.1%)。改良组12个月无进展生存率为46.1%,未达预设疗效阈值,但组间非正式比较未提示疗效降低。
要点
- 改良伊匹木单抗组3-5级治疗相关不良事件发生率显著低于标准组(32.8% vs 53.1%)。
- 改良组12个月无进展生存率为46.1%(90% CI 38.6-53.2),未达预设疗效阈值。
- 非正式比较未提示改良方案疗效降低,但研究未设计正式比较两组疗效。
核心结论
- 改良伊匹木单抗组3-5级治疗相关不良事件发生率显著低于标准组。
- 改良组12个月无进展生存率未达预设疗效阈值,但组间非正式比较未提示疗效降低。
研究设计与样本
- 随机II期试验,将初治晚期透明细胞肾细胞癌患者按2:1随机分配接受改良(每12周一次)或标准(每3周一次)伊匹木单抗1 mg/kg联合纳武利尤单抗3 mg/kg治疗,共4剂伊匹木单抗。
- 2018年3月至2020年1月共192例患者随机分配并接受至少一剂研究药物,其中69.8%为中/高危。
- 主要终点为接受至少一剂治疗者中3-5级治疗相关不良事件的比例;关键次要终点为改良组12个月无进展生存率与历史舒尼替尼对照比较。
- 研究未设计正式比较两组疗效。
主要发现
- 改良组3-5级治疗相关不良事件发生率为32.8%,标准组为53.1%(比值比0.43,90% CI 0.25-0.72;P=0.0075)。
- 改良组12个月无进展生存率为46.1%(90% CI 38.6-53.2)。
- 中位随访21个月时,改良组与标准组的总缓解率分别为45.3%与35.9%,中位无进展生存期分别为10.8个月与9.8个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究未设计正式比较两组疗效。
- 改良组12个月无进展生存率未达预设疗效阈值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Ipilimumab (IPI), in combination with nivolumab (NIVO), is an approved frontline treatment option for patients with intermediate- or poor-risk advanced renal cell carcinoma (aRCC). We conducted a randomized phase II trial to evaluate whether administering IPI once every 12 weeks (modified), instead of once every 3 weeks (standard), in combination with NIVO, is associated with a favorable toxicity profile. METHODS: Treatment-naïve patients with clear-cell aRCC were randomly assigned 2:1 to receive four doses of modified or standard IPI, 1 mg/kg, in combination with NIVO (3 mg/kg). The primary end point was the proportion of patients with a grade 3-5 treatment-related adverse event (trAE) among those who received at least one dose of therapy. The key secondary end point was 12-month progression-free survival (PFS) in the modified arm compared with historical sunitinib control. The study was not designed to formally compare arms for efficacy. RESULTS: Between March 2018 and January 2020, 192 patients (69.8% intermediate/poor-risk) were randomly assigned and received at least one dose of study drug. The incidence of grade 3-5 trAEs was significantly lower among participants receiving modified versus standard IPI (32.8% v 53.1%; odds ratio, 0.43 [90% CI, 0.25 to 0.72]; P = .0075). The 12-month PFS (90% CI) using modified IPI was 46.1% (38.6 to 53.2). At a median follow-up of 21 months, the overall response rate was 45.3% versus 35.9% and the median PFS was 10.8 months versus 9.8 months in the modified and standard IPI groups, respectively. CONCLUSION: Rates of grade 3-5 trAEs were significantly lower in patients receiving modified versus standard IPI. Although 12-month PFS did not meet the prespecified efficacy threshold compared with historical control, informal comparison of treatment groups did not suggest any reduction in efficacy with the modified schedule.
引用
- Vasudev NS, Ainsworth G, Brown S, et al. Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM). J Clin Oncol. 2023. PMID: 37931206. doi:10.1200/JCO.23.00236
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。